查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1136915

全球疫苗輸送設備市場-2022-2029

Global Vaccine Delivery Devices Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場動態

疫苗輸送設備市場的增長是由各種傳染病（如 COVID-19）的流行、老年人口的增加以及研發活動推動的。

公眾對疫苗接種意識的提高有望推動市場增長

國家免疫意識月 (NIAM) 在 8 月份慶祝，預計在預測期內，COVID-19 等疾病的流行病不斷上升將提振市場。根據 NIAM 2021 數據，隨著全國范圍內 COVID-19 病例的增加，有必要接種疫苗。 NIAM 鼓勵國家免疫意識，並討論增加針對 COVID 以及白喉、麻疹、腮腺炎、脊髓灰質炎、風疹和破傷風等疾病的免疫接種的策略。該策略包括接觸服務不足的社區，鼓勵對兒科患者進行年度篩查，並倡導維持免疫計劃以減少對疫苗接種的猶豫。我在這裡。

此外，主要參與者正在採用收購和產品開發等市場策略。例如，2020 年 4 月，新西蘭製藥公司以 2300 萬美元收購了美國醫療保健公司 Valeritas Holdings。同樣在 2021 年 11 月，Gelesheimer 與 Midas Pharma 合作開發了一種新的自動注射器。該合作夥伴關係包括新一代自動注射器的開發和營銷。

此外，2021 年 8 月，印度疫苗開發商 Serum Institute 收購了醫藥包裝公司 Schott Kaisha 50% 的股份，收購金額未披露。 Schott 是一家德國生產商，生產藥瓶、注射器和藥筒。

缺乏疫苗輸送設備阻礙了市場增長

但是，由於某些疾病的先進治療方法，許多人無法獲得醫療保健。例如，由 Biogen 銷售並用於治療脊髓性肌萎縮症的 SPINRAZA，第一年每位患者的費用約為 750,000 美元，或每年 375,000 美元。這些因素對市場增長產生負面影響。

COVID-19 影響分析

COVID-19 的出現對全球疫苗輸送設備市場產生了相當大的影響。

根據 2021 年 11 月的 PATH 數據報告，COVID-19 疫苗注射器的需求激增，預計從 2021 年底到 2022 年年中將超過 40 億支，這是由疫苗 COVAX、政府的大量捐款推動的, 二 這是由於通過國際貿易向國家提供的 COVID-19 疫苗劑量估計增加。 PATH 模型根據全球供需數據估計全球缺口為 12 億支 AD 注射器。例如，2021 年 11 月，New PATH Modeling 預測全球市場供應缺口為 12 億個用於 COVID-19 疫苗交付的自動停用注射器安全注射裝置。這一差距可能會導致中斷，從而危及全球疫苗的及時交付。

另一方面，注射器供應面臨的任何挑戰，例如出口限制、發貨延遲、新生產線不符合世界衛生組織的指導方針或延遲完成計劃的生產擴張，都會在此期間累積。可能會增長到超過 20 億。加強劑量還會對市場造成額外的需求壓力。

通過全球疫苗輸送設備市場報告，您將可以訪問大約 65 多個市場數據表、65 多個圖表和 200 多個頁面（大約）。

內容

第一章市場研究方法和範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第 4 章市場動態

  • 市場影響因素
    • 驅動程序
      • 技術進步
      • 對疫苗輸送設備的需求增加
    • 約束因素
      • 疫苗輸送設備成本高
    • 影響分析

第五章行業分析

  • 波特五力分析
  • 供應鏈分析
  • 法律法規分析
  • 定價分析
  • 未滿足的需求分析

第 6 章 COVID-19 分析

  • COVID-19 的市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按產品類型

  • 噴射噴射器
  • 注射器
  • 微針
  • 其他

第 8 章給藥途徑

  • 皮下接種
  • 肌內接種
  • 皮內接種
  • 無針配方
  • 其他

第 9 章，最終用戶

  • 醫院
  • 社區中心
  • 研究和學術機構
  • 門診手術中心
  • 其他

第十章分銷渠道

  • 醫院
  • 在線藥店
  • 零售藥房
  • 醫院藥房
  • 疫苗接種中心

第 11 章按地區劃分

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 12 章競爭格局

  • 主要發展和戰略
  • 公司份額分析
  • 按治療類型劃分的基準

第 13 章公司簡介

  • 3M
    • 公司簡介
    • 治療類型組合和描述
    • 主要亮點
    • 財務摘要
  • Becton Dickinson & Company
  • Inovio Pharmaceutical Inc.
  • PharmaJet
  • Vaxxas
  • Gerresheimer AG
  • SCHOTT AG
  • Corium International, Inc.
  • Intravaac

第 14 章全球疫苗輸送設備市場-DataM

簡介目錄
Product Code: DMMD819

Market Overview

Vaccine Delivery Devices Market size was valued at US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 7.2% during the forecast period (2022-2029).

The vaccine delivery device is used for proper vaccine delivery to ensure successful vaccination. Mainly, most vaccines are administered via the subcutaneous (SC) or intramuscular (IM) routes.

Market Dynamics

The vaccine delivery devices market growth is driven by the rise in the prevalence of different infectious diseases, such as COVID-19, an increase in the geriatric population, and research and development activities.

The rising awareness of immunizations in public is expected to drive the market growth

The increasing prevalence of diseases, such as COVID-19, is expected to boost the market over the forecast period. National Immunization Awareness Month (NIAM) is celebrated in August month. As per NIAM 2021 data, COVID-19 cases are increasing nationwide, so it is necessary to take the vaccination. NIAM encourages National Immunization Awareness and discusses strategies for increasing immunizations for COVID and other diseases such as diphtheria, measles, mumps, polio, rubella, and tetanus, among others diseases. The strategies include local outreach to underreserved communities to reduce vaccine hesitancy, encouraging annual checkups of pediatric patients, and advocating to keep up the immunization schedule.

In addition, the key players are adopting the market strategies such as acquisition and product development. For instance, in April 2020, Zealand Pharma acquired Valeritas Holdings, a U.S.-based medical company, for USD 23 Mn. Also, in November 2021, Gerresheimar partnered with Midas Pharma for a new auto-injector. The partnership contains the development and marketing of a new-generation auto-injector.

Furthermore, in August 2021, the Vaccine developer Serum Institute of India acquired a 50% stake in pharma packaging company Schott Kaisha for an amount that was not disclosed. Schott AG is a Germany-based player that manufactures vials, syringes, and cartridges.

The shortage of vaccine delivery devices will hamper the growth of the market

However, many people cannot afford healthcare due to advanced treatment for several diseases. For instance, the cost of Spinraza, marketed by Biogen and used for the treatment of spinal muscular atrophy, is around US$ 750,000 per patient in the first year and US$ 375,000 annually. These factors negatively affecting on market growth.

COVID-19 Impact Analysis

The appearance of COVID-19 considerably impacted the global vaccine delivery devices market.

According to November 2021 PATH data report, the expected spike in demand for syringes for COVID-19 vaccines, anticipated to total more than 4 billion from the year-end of 2021 to mid-2022, is due to the estimated increase in COVID-19 vaccine dose deliveries to countries coming through vaccine COVAX, large donations from governments, and bilateral deals. The PATH modeling estimates a global gap of 1.2 billion AD syringes based on global supply and demand data. For instance, in November 2021, New PATH modeling anticipates a global market supply gap of 1.2 billion auto-disable syringe safe-injection devices for COVID-19 vaccine delivery. This gap risks becoming a stoppage that could risk the timely delivery of vaccines in countries worldwide.

On the other hand, challenges to syringe supply, such as export restrictions, shipping delays, new manufacturing lines failing to receive World Health Organization guidelines, or delays in completing planned manufacturing expansions, could broaden the cumulative gap to more than 2 billion during this period. Also, Booster doses could create further demand pressures on the market.

Segment Analysis

The microneedles segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The microneedles segment is expected to boost the market throughout the forecast. As per the article published in Pharmaceutics 2022, the maintenance of the vaccine potency, transportation, and needle waste generation have become major issues. Moreover, needle phobia and vaccine hesitancy are hurdles to successful mass vaccination. Dissolvable microneedles for vaccination could act as a major paradigm shift in attaining the desired goal of vaccinating billions in the shortest time possible.

Using dissolvable microneedle patches would improve the dosing accuracy, ensuring the precise delivery of the vaccines. Using biodegradable microneedles for transdermal immunization is a fast-developing topic of study and application. Microneedles have several benefits over traditional immunization, such as intramuscular and subcutaneous injections, aside from the fact that they are painless, slowing the release of vaccination antigens. Vaccine components in microneedles may be in solution or suspension, coated in nano or microparticles, or based on nucleic acids. Due to the combined advantages of particulate vaccinations and pain-free vaccination, the use of microneedles to administer particle-based immunizations is growing rapidly.

In addition, in May 2020, Altaris Capital Partners acquired Kindeva Drug Delivery for $650 million. With the help of the expertise of 3M and the Kindeva team, Altaris able to develop innovative drug delivery technologies in the healthcare sector.

Geographical Analysis

North America region holds the largest market share of the global vaccine delivery devices market

North America dominates the market for vaccine delivery devices and is expected to show a similar trend over the forecast period. It is anticipated to hold a significant market size over the forecast period (2022-2029) owing to advanced healthcare infrastructure, rising chronic and infectious diseases, and launching new products. The presence of market players and government initiatives for public health drives the market. For instance, the United States government has ordered 286 million needles and syringes from B.D., with 256 million to be given by January 2021. These devices will help to deliver a safe, effective COVID-19 vaccine to millions of Americans as soon as one is available. In July 2020, ASPR's Biomedical Advanced Research and Development Authority (BARDA) invested approximately $42 million into a $70 million capital project to further expand B.D.'s operations and manufacturing lines in Holdrege, Neb. The expansion builds on the company's deep commitment and legacy in supporting U.S. vaccination efforts through the domestic manufacturing of needles and syringes.

Competitive Landscape

The vaccine delivery devices market is a moderately competitive presence of local and global companies. Some of the key players contributing to the market's growth are 3M, Becton Dickinson & Company, Inovio Pharmaceutical Inc., PharmaJet, Vaxxas, Gerresheimer AG, SCHOTT AG, Corium International, Inc. and Intravaac, among others. The major players are adopting several growth strategies, such as product launches, acquisitions, and collaborations, contributing to the growth of the global vaccine delivery devices market.

For instance,

  • In 2021, Rockwell industries launched the world's hybrid freezer, which is used to store the COVID-19 vaccine.
  • In 2021, Becton and Dickison launched a needles & syringes multi-drug delivery facility device that helps administer COVID-19 vaccines.

Becton Dickinson & Company

Overview:

Becton Dickinson & Company is an American multinational medical technology company headquartered in the United States that provides advancing health solutions for patient safety and clinical outcomes. It offers the vaccine syringe and other drug delivery systems in the market.

Product Portfolio:

BD Hypak: It is used for vaccines glass pre-fillable syringe system, a reliable glass pre-fillable syringe system specifically optimized for vaccinations. The system fulfills customer needs for better processability of the syringe during filling and packaging operations.

The global vaccine delivery devices market report would provide access to approximately 65+ market data tables, 65+ figures, and in the range of 200+ (approximate) pages.

Table of Contents

1. Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Technological advancements
      • 4.1.1.2. Rising demand for vaccine delivery devices
    • 4.1.2. Restraints:
      • 4.1.2.1. High cost of Vaccine Delivery Devices
    • 4.1.3. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis
  • 5.4. Pricing Analysis
  • 5.5. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Product Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 7.1.2. Market Attractiveness Index, By Product Type
  • 7.2. Jet Injectors*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Syringes
  • 7.4. Microneedles
  • 7.5. Others

8. By Route of Administration

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 8.1.2. Market Attractiveness Index, By Route of Administration
  • 8.2. Subcutaneous Vaccination*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Intramuscular Vaccination
  • 8.4. Intra Dermal Vaccination
  • 8.5. Needle Free Delivery
  • 8.6. Others

9. By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.1.2. Market Attractiveness Index, By End User
  • 9.2. Hospitals*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Community Centers
  • 9.4. Research and Academic Institutes
  • 9.5. Ambulatory Surgical Center
  • 9.6. Others

10. By Distribution Channel

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.1.2. Market Attractiveness Index, By Distribution Channel
  • 10.2. Hospitals*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Online Pharmacies
  • 10.4. Retail Pharmacies
  • 10.5. Hospital Pharmacies
  • 10.6. Vaccination Centers

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. The U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

12. Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Treatment type Benchmarking

13. Company Profiles

  • 13.1. 3M*
    • 13.1.1. Company Overview
    • 13.1.2. Treatment type Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Becton Dickinson & Company
  • 13.3. Inovio Pharmaceutical Inc.
  • 13.4. PharmaJet
  • 13.5. Vaxxas
  • 13.6. Gerresheimer AG
  • 13.7. SCHOTT AG
  • 13.8. Corium International, Inc.
  • 13.9. Intravaac

LIST NOT EXHAUSTIVE

14. Global Vaccine Delivery Devices market- DataM

  • 14.1. Appendix
  • 14.2. About Us and Services
  • 14.3. Contact Us